<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3C83A8CE-8C98-462F-BD2D-7E8E5B913716"><gtr:id>3C83A8CE-8C98-462F-BD2D-7E8E5B913716</gtr:id><gtr:name>Chirotech Technology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C2BD79F-F24F-44CF-AA2C-F7B414D10861"><gtr:id>9C2BD79F-F24F-44CF-AA2C-F7B414D10861</gtr:id><gtr:name>Bioethanol Science and Technology Centre (CTBE)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5FD8030D-A271-42C1-B9E0-1DC1FEDADCA5"><gtr:id>5FD8030D-A271-42C1-B9E0-1DC1FEDADCA5</gtr:id><gtr:name>Cobra Biologics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A080F79-7EED-4D18-8137-B13676266157"><gtr:id>4A080F79-7EED-4D18-8137-B13676266157</gtr:id><gtr:name>Biocatalysts Ltd</gtr:name><gtr:address><gtr:line1>Biocatalysts Ltd</gtr:line1><gtr:line2>Unit 1</gtr:line2><gtr:line3>Cefn Coed, Nantgarw</gtr:line3><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF15 7QQ</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>School of Medical Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3C83A8CE-8C98-462F-BD2D-7E8E5B913716"><gtr:id>3C83A8CE-8C98-462F-BD2D-7E8E5B913716</gtr:id><gtr:name>Chirotech Technology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C2BD79F-F24F-44CF-AA2C-F7B414D10861"><gtr:id>9C2BD79F-F24F-44CF-AA2C-F7B414D10861</gtr:id><gtr:name>Bioethanol Science and Technology Centre (CTBE)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5FD8030D-A271-42C1-B9E0-1DC1FEDADCA5"><gtr:id>5FD8030D-A271-42C1-B9E0-1DC1FEDADCA5</gtr:id><gtr:name>Cobra Biologics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A080F79-7EED-4D18-8137-B13676266157"><gtr:id>4A080F79-7EED-4D18-8137-B13676266157</gtr:id><gtr:name>Biocatalysts Ltd</gtr:name><gtr:address><gtr:line1>Biocatalysts Ltd</gtr:line1><gtr:line2>Unit 1</gtr:line2><gtr:line3>Cefn Coed, Nantgarw</gtr:line3><gtr:line4>Cardiff</gtr:line4><gtr:postCode>CF15 7QQ</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2FCA0B9D-369C-4CC5-BD69-BE5BD73A9B44"><gtr:id>2FCA0B9D-369C-4CC5-BD69-BE5BD73A9B44</gtr:id><gtr:firstName>Neil</gtr:firstName><gtr:surname>Dixon</gtr:surname><gtr:orcidId>0000-0001-9065-6764</gtr:orcidId><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FK014773%2F1"><gtr:id>317FD60E-2883-4D22-88C0-FDB8D3681F0E</gtr:id><gtr:title>Development and Application of Next Generation Synthetic Biology Tools</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>BB/K014773/1</gtr:grantReference><gtr:abstractText>A variety of micro-organisms including E. coli and S. cerevisiae (baker's yeast), are used in commercial bio-production processes to manufacture a number of products, ranging from high-value low-volume products, such bio-therapeutics (e.g. recombinant insulin), to mid-value products, (e.g. biocatalysts and specialised chemicals), to low-value bulk commodity products (e.g. succinic acid and biofuels). In addition, the same biotechnologies used in these production processes are commonly used in basic life science research. As such, the development of new gene control systems would be of great benefit in a number of applied and fundamental areas of biological and biomedical R&amp;amp;D. In particular, the research here seeks to develop novel protein production and metabolic engineering tools, and to demonstrate the applications of these novel synthetic biology tools in the context of the bioprocessing industry. 

Within the pharmaceutical sector, biopharmaceuticals constitute 7 out of the 10 bestselling products. The global protein-based biopharmaceutical market had sales worth $70b in 2010, and this figure is set to increase to $110b by 2015. The reasons for the increase in projected global sales are thus: i) many of the targets of these therapeutic proteins are deemed 'undruggable' by traditional small molecule approaches, ii) therapeutic proteins often have superior safety and efficacy profiles, iii) the development times on average are shorter for therapeutic proteins than traditional therapies, iv) there is often limited or absent competition. However, although biopharmaceuticals offer many health benefits along with substantial commercial opportunities, their production remains a significant technical challenge. 

Through this current study, I shall develop and demonstrate four important flavours of a novel gene co-expression technology, to allow multimeric protein products to be produced more effectively, along with the potential to provide a simpler and more efficient manufacturing process. Additionally, these co-expression technologies will be used to optimise a number of multivariate co-expression challenges, helping to guide metabolic engineering efforts. The outputs from this fellowship will lead to improved bioprocess efficiencies, with the potential to reduce both drug development times and manufacturing costs, and therefore the financial burden upon national healthcare providers. This research project will also generate technology and knowledge that will help maintain the UK's competitive edge, and will produce highly trained and skilled research personnel.</gtr:abstractText><gtr:technicalSummary>This project will involve the development and application of a series of novel gene expression control biotechnologies in E. coli, to provide feedback control and multiple gene co-expression control for the controlled enhancement of the expression of multiple and/or difficult proteins. This work will include examples of practical application of these tools and systems for use in academia, the bioprocessing sector and other areas of the knowledge based bio-economy. Results from this study will also enable fundamental questions regarding bacterial physiology, stress response mechanisms and pathway flux engineering to be addressed, resulting in the establishment of a strong independent research career.

Firstly, a modular co-expression platform will be developed, which utilise the unique translational control of previously-developed orthogonal riboswitches, to regulate the expression of multiple viral RNA polymerases. This platform will be demonstrated by controlling the co-expression stoichiometry of the heavy and light chains of a Fab' antibody fragment. Secondly, a stress response sensing feedback system will be developed, utilizing a trans-acting antisense ncRNA input signal to permit recombinant gene expression to be matched to cellular synthetic capacity, enabling auto-regulatory optimisation of high-density fermentation cultures. Thirdly, multivariate pathway flux engineering will be used, in parallel with transcriptome profiling, to optimise glycosylation of proteins of bio-therapeutic importance within E. coli. Finally, a proof-of-principle study will seek to demonstrate the potential of using the bacterial c-di-GMP allosteric self-splicing ribozyme from C. difficile as a gene expression tool within a eukaryotic background. The systems developed here will be demonstrated with a number of practical examples of interest, and under fermentation conditions of relevance to the bioprocessing sector.</gtr:technicalSummary><gtr:potentialImpactText>WHO WILL BENEFIT: Pharmaceutical, biotech and contract manufacturing organisations charged with producing human therapeutic proteins on the hundred gram to kilogram scale could also use the co-expression systems developed here to produce biopharmaceuticals in E. coli. Interest from industry members has indicated how these technologies could find application in protein-based biopharmaceutical production processes. Drug discovery companies would benefit from novel co-expression technologies that permit the supply of toxic and/or insoluble drug targets e.g. Domainex. Additionally, many chemical companies that employ biocatalysts, such as Novozymes, DSM, Lonza, BASF and Dr. Reddy's, could also use these new co-expression tools for the production of multi-subunit enzymes. Similarly, oil companies such as Shell and BP have invested heavily in synthetic biology programmes to engineer microorganisms to produce new biofuels, where new co-expression tools would be equally important. Finally, there are many companies, such as Invitrogen, Qiagen, Promega, Stratagene, EMD Bioscience, Thermo Fisher, Bio-Rad, GE healthcare and Sigma-Aldrich, who sell commercial expression systems for use in bacteria. Any number of these companies could benefit through licensing agreements to use new systems based on the co-expression technologies developed in this project. 

HOW WILL THEY BENEFIT: We will actively seek to communicate our findings to the wider community, through scientific meetings and scholarly publications (by continuing to publish in top journals such as: JACS, PNAS, Nat Biotechnol. &amp;amp; Nature Chem. Biol.). However, in order for the technology we develop to become widely adopted, particularly in industry, it will be important to first secure any intellectual property rights for all new inventions we discover. As the research progresses and our relationships with interested commercial partners develop, we will seek to commercially exploit these new technologies and license the IP for use in industrial-scale protein production processes. Improvements in bioprocess efficiency, generated from this fellowship, could lead to a potential reduction in both drug manufacturing costs and the financial burden upon national healthcare providers. This research project will also generate technology and knowledge that will help maintain the UK's competitive edge and will produce highly trained and skilled research personnel.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2013-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1101823</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chirotech Technology</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AS project</gtr:description><gtr:id>0D586112-E458-481E-BED9-A16DEE3A544D</gtr:id><gtr:impact>Too early</gtr:impact><gtr:outcomeId>5633a61152e8f5.80992914-2</gtr:outcomeId><gtr:partnerContribution>Supply of materials to enable the research to proceed and desk analysis of commercial viability of the processes to be developed as part of the research.</gtr:partnerContribution><gtr:piContribution>The research project.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cobra Biologics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with CMO for biologics production</gtr:description><gtr:id>687D0035-45FB-4950-B1F8-63C236DCD379</gtr:id><gtr:impact>Too earlier to say, the collaboration has led to successful joint grant funding.</gtr:impact><gtr:outcomeId>545c9e711e2887.63519126-1</gtr:outcomeId><gtr:partnerContribution>The partners have contributed industry R&amp;amp;D and know-how</gtr:partnerContribution><gtr:piContribution>We have contributed IP, know-how, and research expertise to this collaboration</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bioethanol Science and Technology Centre (CTBE)</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>Collaboration with CTBE, Brazil</gtr:description><gtr:id>3B80ED06-4EDC-4CF9-94FE-6F98A2B674C0</gtr:id><gtr:impact>Outcomes: A proposed funding application to the BBSRC/FAPESP (&amp;gt;&amp;pound;2.5 UK). 
Multi-discplianry collaboration: Synthetic Biology, Meta-transcriptomics, Enzyme discovery, biocatalysis, bioprocess development, life-cycle analysis.</gtr:impact><gtr:outcomeId>5633955d2aea98.76362817-1</gtr:outcomeId><gtr:partnerContribution>During a Faculty-led Research Development visit to Brazil, we visited the Brazilian National Laboratory for Bioethanol (CTBE). Following this visit, myself and Fabio Squina (CTBE) have been in communication about applying ours interests in synthetic biology to facilitate enzyme discovery associated with lignin-biomass valorisation. We hosted visitors from the CTBE and other research institutes in Brazil at Industrial Biotechnology Bioenergy Meeting that I co-organised. This led to a successful funding application to the BBSRC/FAPESP (FAPPA) pump-priming call, to allow us to explore these preliminary ideas and facilitate further networking and research consortia building activities. Most recently we re-visited the CTBE to further develop collaborators links and build a research proposal. This has led to exchange of materials, a proposed exchange of personnel between my laboratory and the CTBE, and most recently to a large funding application to the BBSRC/FAPESP (&amp;gt;&amp;pound;2.5 UK).</gtr:partnerContribution><gtr:piContribution>During a Faculty-led Research Development visit to Brazil, we visited the Brazilian National Laboratory for Bioethanol (CTBE). Following this visit, myself and Fabio Squina (CTBE) have been in communication about applying ours interests in synthetic biology to facilitate enzyme discovery associated with lignin-biomass valorisation. We hosted visitors from the CTBE and other research institutes in Brazil at Industrial Biotechnology Bioenergy Meeting that I co-organised. This led to a successful funding application to the BBSRC/FAPESP (FAPPA) pump-priming call, to allow us to explore these preliminary ideas and facilitate further networking and research consortia building activities. Most recently we re-visited the CTBE to further develop collaborators links and build a research proposal. This has led to exchange of materials, a proposed exchange of personnel between my laboratory and the CTBE, and most recently to a large funding application to the BBSRC/FAPESP (&amp;gt;&amp;pound;2.5 UK).</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Biocatalysts Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AS project</gtr:description><gtr:id>EE1E99FC-22EF-43ED-8011-5AEFAF1243E7</gtr:id><gtr:impact>Too early</gtr:impact><gtr:outcomeId>5633a61152e8f5.80992914-1</gtr:outcomeId><gtr:partnerContribution>Supply of materials to enable the research to proceed and desk analysis of commercial viability of the processes to be developed as part of the research.</gtr:partnerContribution><gtr:piContribution>The research project.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Institute Open Day (Outreach)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7E1DB611-D747-4CEF-92A0-F60C639D8341</gtr:id><gtr:impact>Prepare promotional material in advance of the meeting, and hosted the interactive stand 1,5 days

tbc</gtr:impact><gtr:outcomeId>545ca145c8c4f3.97875681</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EuroScience Open Forum (ESOF)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D3C0B0D3-5E9D-4BDD-B6B8-7CF1D240C59E</gtr:id><gtr:impact>EuroScience Open Forum (ESOF):

+provide an open forum for debate on science and technology and research policies in Europe
+strengthen the links between science and society
+contribute to the creation of an integrated space for science and technology in Europe, linking research organisations and policies at national and EU levels; strive for a greater role of the EU in research and
+influence science and technology policies.</gtr:impact><gtr:outcomeId>58b5301b4f9b69.15802962</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://manchester2016.esof.eu/en/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Institute Open Day (Outreach)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E93E7818-6B59-4438-93C1-299A4721EB03</gtr:id><gtr:impact>Synthetic Biology stand at MIB open-day attended by &amp;gt;200 A levels students</gtr:impact><gtr:outcomeId>58b52f120ae867.97110822</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SynBioChem Workshop on Responsible Research and Innovation</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>809F520F-B72E-4358-BEAF-7EA61D3AD519</gtr:id><gtr:impact>Roundtable discussant at SynBioChem Workshop on Responsible Research and Innovation</gtr:impact><gtr:outcomeId>58b531118e29c5.61120045</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SMART-Map Industrial Dialogue on Synthetic Biology</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>64844280-AF40-47E6-BA34-CF464E4713D2</gtr:id><gtr:impact>Workshop on the responsible development of Synthetic Biology which forms part of the EU H2020 SMART-map project.</gtr:impact><gtr:outcomeId>58b531747ac559.43406467</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:url>http://projectsmartmap.eu/</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>FLS Community Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1BC63FC5-5FB5-4746-A063-D9A9FA1841EB</gtr:id><gtr:impact>An outreach stand about biotechnology for the production of fragrance compounds and public opinion of synthetic biology</gtr:impact><gtr:outcomeId>58b530a0720bb3.63761938</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>iGEM Giant Jamboree</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6F8DB095-4C55-4878-80D2-0551C820AA3A</gtr:id><gtr:impact>Synthetic Biology iGEM Giant Jamboree</gtr:impact><gtr:outcomeId>58b52f831e1a43.48228669</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://2016.igem.org/Giant_Jamboree</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>35032</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Networks in Industrial Biotechnology and Bioenergy (NIBB)</gtr:department><gtr:description>Proof of Concept - CMBNet</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BIOCATNET PoC-012	</gtr:fundingRef><gtr:id>AE8A0885-9ECE-4271-840E-F3BC26DBDC55</gtr:id><gtr:outcomeId>58b52c09456478.06626108</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC CDT UCL</gtr:description><gtr:end>2020-08-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>77E8B9B2-890A-4DEA-9200-70833A73B260</gtr:id><gtr:outcomeId>563397c22da217.95440907</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Synthetic Biology Centre Bid 2</gtr:description><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/M017702/1</gtr:fundingRef><gtr:id>605E98B1-7033-48BB-9662-390D0D1805D5</gtr:id><gtr:outcomeId>5633a428452014.42796914</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2082439</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC-FAPESP joint call in advanced biofuels</gtr:description><gtr:end>2022-02-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/P01738X/1</gtr:fundingRef><gtr:id>77104DA6-44BB-4424-A806-1B7E40D11CAF</gtr:id><gtr:outcomeId>58b53b53e69f96.72322848</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>121512</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IB Catalyst - Early Stage Feasibility</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/M011259/1</gtr:fundingRef><gtr:id>633A3BFE-E810-4038-BC7B-D787FBF52E64</gtr:id><gtr:outcomeId>560a99abf38a65.15257836</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Science Without Boarders</gtr:description><gtr:end>2020-08-02</gtr:end><gtr:fundingOrg>National Council for Scientific and Technological Development (CNPq)</gtr:fundingOrg><gtr:id>9A7C8CC6-3A88-4B31-ACEF-F0260669207D</gtr:id><gtr:outcomeId>5633968aa060e9.29907999</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35032</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BioCatNet Proof of Concept</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>56A05FA2-468E-41D8-B470-34429E6882CB</gtr:id><gtr:outcomeId>56339620cefea1.52913260</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>Indonesia, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Indonesian Government Home funded PhD Srudenship</gtr:description><gtr:end>2020-08-02</gtr:end><gtr:fundingOrg>Government of Indonesia</gtr:fundingOrg><gtr:id>030FC0C5-DB07-470D-BE5D-42BDA438C689</gtr:id><gtr:outcomeId>58b532f0486e37.33655540</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC, DTP</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>605FCB1B-0271-4136-BF1C-8F1106E3CF44</gtr:id><gtr:outcomeId>5633984d37cfc6.49755953</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Has led to the adoption of new working practices within the industrial collaborators UK-based R&amp;amp;D facility, which has led to new business opportunities.</gtr:description><gtr:firstYearOfImpact>2014</gtr:firstYearOfImpact><gtr:id>EC40EF8C-E5EF-4F8A-85B1-A8D19FCF190F</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>545ccea13a9e99.92642246</gtr:outcomeId><gtr:sector>Manufacturing, including Industrial Biotechology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Too early in the project to say, the findings are currently being prepared for publication in Open Access journals - this information will be expanded upon when the work is in the public domain.</gtr:description><gtr:exploitationPathways>In the following research areas and industrial sectors: Applied Biotechnology, protein production, industrial biotechnology</gtr:exploitationPathways><gtr:id>B87DFDB7-E153-4CC2-A8FC-1119D38176A4</gtr:id><gtr:outcomeId>545cce72b68267.36303498</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>438A645E-60EC-49B9-8039-655B77E2CED3</gtr:id><gtr:title>Optimization of Membrane Protein Production Using Titratable Strains of E. coli.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d1d07af39adeceda3a6e1b6a6c44e36"><gtr:id>7d1d07af39adeceda3a6e1b6a6c44e36</gtr:id><gtr:otherNames>Morra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>5a9800348e35f5.24424681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1D203FE-0369-4952-A628-7C95502D6015</gtr:id><gtr:title>Partial Least Squares with Structured Output for Modelling the Metabolomics Data Obtained from Complex Experimental Designs: A Study into the Y-Block Coding.</gtr:title><gtr:parentPublicationTitle>Metabolites</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d0cd56c5d6f324ffe01776b7518642ba"><gtr:id>d0cd56c5d6f324ffe01776b7518642ba</gtr:id><gtr:otherNames>Xu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2218-1989</gtr:issn><gtr:outcomeId>5a735395f3e763.15418923</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B00D3A16-6EC3-4837-81FF-EC0A17FBF07B</gtr:id><gtr:title>Dual transcriptional-translational cascade permits cellular level tuneable expression control.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d1d07af39adeceda3a6e1b6a6c44e36"><gtr:id>7d1d07af39adeceda3a6e1b6a6c44e36</gtr:id><gtr:otherNames>Morra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>560a96a0ed6142.25341491</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A19DFA86-3D41-4BF5-B974-E82A0E3D50F9</gtr:id><gtr:title>Generation of orthogonally selective bacterial riboswitches by targeted mutagenesis and in vivo screening.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23690bee8bb4b9c5c4c98396af52bad9"><gtr:id>23690bee8bb4b9c5c4c98396af52bad9</gtr:id><gtr:otherNames>Vincent HA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>545cc8d6632a08.22897714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F29FF65B-8822-4B87-B5D0-18BAB955F4BA</gtr:id><gtr:title>Translation Stress Positively Regulates MscL-Dependent Excretion of Cytoplasmic Proteins.</gtr:title><gtr:parentPublicationTitle>mBio</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d1d07af39adeceda3a6e1b6a6c44e36"><gtr:id>7d1d07af39adeceda3a6e1b6a6c44e36</gtr:id><gtr:otherNames>Morra R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a97fff7249122.48761113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CEE0A49-17AD-4BE5-BF06-1CCD9D7177A0</gtr:id><gtr:title>Metabolomic analysis of riboswitch containing E. coli recombinant expression system.</gtr:title><gtr:parentPublicationTitle>Molecular bioSystems</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/75af8586909c9dee4e4e4ea4c3e50135"><gtr:id>75af8586909c9dee4e4e4ea4c3e50135</gtr:id><gtr:otherNames>Muhamadali H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1742-2051</gtr:issn><gtr:outcomeId>56338f45b5e286.19774837</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/K014773/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>17F21DBC-4946-4262-AD07-9914F6EA12F7</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Bioengineering</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>F442B6BE-8B89-4C01-8D3B-E8A4D320B672</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biomolecules &amp; biochemistry</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>18D298A9-FFE3-432F-B077-E3B703272E29</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Biochemical engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>02567418-12CB-462E-9092-530C6E63B359</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Chemical Biology</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>19C5179C-0522-47E8-82DA-48583B56264E</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Metabolic engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>9031EBB8-791D-4466-9E80-80F98BCB26E1</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Protein expression</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>